Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene
about
An overview of the serpin superfamilyPlasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic TestingBleeding related to disturbed fibrinolysisPlasminogen activator inhibitor 1 RNAi suppresses gastric cancer metastasis in vivo.Plasminogen activator inhibitor-1 (PAI-1) is cardioprotective in mice by maintaining microvascular integrity and cardiac architecture.Hemostatic function to regulate perioperative bleeding in patients undergoing spinal surgery: A prospective observational studyEffects of whole-body vibration training on fibrinolytic and coagulative factors in healthy young men.PAI-1 antagonists: the promise and the peril.A serpin shapes the extracellular environment to prevent influenza A virus maturationProcoagulant activity in hemostasis and thrombosis: Virchow's triad revisited.Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity.Chemical Antagonists of Plasminogen Activator Inhibitor-1: Mechanisms of Action and Therapeutic Potential in Vascular Disease.Bleeding diathesis is associated with an A15T heterozygous mutation in exon 2 of the plasminogen activator inhibitor type 1.Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction.Do inflammation and procoagulation biomarkers contribute to the metabolic syndrome cluster?Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade.Lack of association between Ser(413)/Cys polymorphism of plasminogen activator inhibitor type 2 (PAI-2) and premature coronary atherosclerotic diseaseTransgenic overexpression of a stable Plasminogen Activator Inhibitor-1 variantImpact of genetic variation on perioperative bleeding.Genomics: risk and outcomes in cardiac surgeryPAI-1 in tissue fibrosis.Low Molecular Weight Antagonists of Plasminogen Activator Inhibitor-1: Therapeutic Potential in Cardiovascular DiseaseRole of Plasminogen Activator Inhibitor Type 1 in Pathologies of Female Reproductive Diseases.Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease.Plasminogen Activator Inhibitor-1 Is a Marker and a Mediator of Senescence.Application of long-acting VLHL PAI-1 during sutureless partial nephrectomy in mice reduces bleeding.Generation of human iPSCs from urine derived cells of patient with a novel heterozygous PAI-1 mutation.Generation of human iPSCs from urine derived cells of a non-affected control subject.Generation of human iPSCs from urine derived cells of a patient with a novel homozygous PAI-1 mutation.A hydrophobic patch surrounding Trp154 in human neuroserpin controls the helix F dynamics with implications in inhibition and aggregation.Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid.Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor-β and Cardiac Fibrosis.A null mutation in SERPINE1 protects against biological aging in humans.
P2860
Q24684030-B7188A60-C8AA-4F6D-B4E5-28D08D12D319Q26801060-5F20FBD2-ED2E-45AD-B3C7-082A2332F105Q28070127-39ACF48C-9E65-41C3-9180-9EE0768E53E5Q33711241-1A3D4779-F1B4-42D0-933D-5F9BE5FCB8BCQ33722735-80C4E48B-3CFE-4AAC-9916-A546D112EC54Q33807064-C28189D8-F79C-42DC-A0AC-2B24CA629F49Q34761223-50D47B61-A935-4812-A539-17ECDC70013BQ35048985-520BD300-41B9-49E2-9FA9-0F619FFE90A1Q35083702-8ABA1474-2492-41FA-8648-DC9EFD8C45E5Q35690807-62908012-DCD5-4439-AB0B-43C8C02335D4Q35711136-2FECFAC6-597A-437C-AD60-048D26AD778EQ35764595-FB045938-FF64-44AD-A328-4B52147D94E5Q36244144-3DF48D3A-0308-4863-8F4A-FB47372102A3Q36370540-C6168B74-D5B2-47FC-9529-361AB2A36054Q36478676-42E93067-5BF4-496C-83CC-E5A682611BB9Q36735157-2CD3D889-8D34-4310-A564-9EB3F9E49656Q37089607-A5A8D6FE-CD1C-43CD-96F2-8B6117FD3572Q37163087-F3DFA49D-FD35-416B-B091-DF30C9C18E4DQ37174998-A280E318-877A-4BA2-9A50-724531A2394EQ37347806-013AA4DC-C961-4365-8841-AB7A8F293EB8Q37861626-DEE1DA99-B117-49CA-9669-6AB1A387C186Q38128321-B804760E-A6D1-4FD4-8D04-9475AB3F8FD5Q38649391-2685F638-B48E-4004-A724-4F3E470DEC8CQ39333523-930ACA1B-330B-4062-998A-341E9BFFE41FQ39344951-FE21CBA4-7CF8-4FAA-A76C-65DAFDCE3E3DQ39453215-10FE8B80-C0F2-4E80-9BCB-ACC0D01D1038Q40249657-85D0EED7-349B-43E7-B280-F0753F536686Q40249665-DDA2A6B8-70D7-47EA-8807-E71B91124A6EQ40416783-FAB694F0-5B86-4C0C-9539-B9E0A1ADCE96Q41854754-D9095FCD-98EF-4F91-8517-5FE7E55352F0Q41877271-9FE5B40F-7D40-4A9D-BFAE-506396FF0CC3Q45868567-BCD373CD-15AA-4B0E-B6E9-FC3E51D44939Q45874700-87D73161-BF80-423E-9A9C-EB448616400E
P2860
Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene
description
1997 nî lūn-bûn
@nan
1997 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Human plasminogen activator in ...... ull mutation in the PAI-1 gene
@ast
Human plasminogen activator in ...... ull mutation in the PAI-1 gene
@en
Human plasminogen activator in ...... ull mutation in the PAI-1 gene
@en-gb
Human plasminogen activator in ...... ull mutation in the PAI-1 gene
@nl
type
label
Human plasminogen activator in ...... ull mutation in the PAI-1 gene
@ast
Human plasminogen activator in ...... ull mutation in the PAI-1 gene
@en
Human plasminogen activator in ...... ull mutation in the PAI-1 gene
@en-gb
Human plasminogen activator in ...... ull mutation in the PAI-1 gene
@nl
prefLabel
Human plasminogen activator in ...... ull mutation in the PAI-1 gene
@ast
Human plasminogen activator in ...... ull mutation in the PAI-1 gene
@en
Human plasminogen activator in ...... ull mutation in the PAI-1 gene
@en-gb
Human plasminogen activator in ...... ull mutation in the PAI-1 gene
@nl
P2093
P3181
P1433
P1476
Human plasminogen activator in ...... ull mutation in the PAI-1 gene
@en
P2093
A C Parker
A D Shapiro
L R Condrey
P3181
P407
P577
1997-07-01T00:00:00Z